Stay updated with breaking news from While Viatris. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Q3 2023 YUPELRI® net sales, recognized by Viatris, increased 9% from Q3 2022, reaching an all-time high of $58.3 million1Progress made towards the achievement of non-GAAP profitability, with Q3...
Q2 2023 YUPELRI® (revefenacin) net sales of $55.0 million, recognized by Viatris, up 12% from Q2 20221 Q2 2023 YUPELRI total retail TRx and new to product TRx...
Increases capital return program to $325 million from $250 million; as of 2/27/23, approximately $170 million remains in the program Discontinuing investments...
These stocks have dividend yields exceeding 4%.
Reported another record quarter of YUPELRI® (revefenacin) net sales and profitability: $18.7 million Q3 2022 sales up 35% from Q3 2021 (TBPH implied 35%...